KASL Consensus Statement for Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatohepatitis: Focus on Semaglutide
Year: 2026
Type: article
Abstract: Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH) impose a rapidly increasing hepatic and cardiometabolic burden worldwide and in Korea. Following the phase 3 ESSENCE trial, which demonstrated the histological efficacy of semaglutide in noncirrhotic MASH with fibrosis, practical guidance for routine clinical care is needed. The Korean Association for the Study of the Liver developed this expert consensus statement on semaglutide treatment in MASH. Using the RAND/UCLA Appropriateness Method, a 15-member expert panel rated 98 clinical scenarios covering patient selection, dosing, response assessment, adverse event management, and metabolic comorbidities over two rating rounds with a structured panel discussion. Semaglutide is primarily intended for patients with noncirrhotic MASH and stage 2-3 fibrosis. Eligibility should be assessed using a two-step strategy of age-adjusted Fibrosis-4 index screening followed by vibration-controlled transient elastography (VCTE). A VCTE-derived liver stiffness measurement (LSM) of 10-15 kPa defines the preferred treatment range; 15-20 kPa is acceptable when cirrhosis and portal hypertension are excluded, whereas 8-10 kPa requires repeat VCTE, magnetic resonance elastography (eligible range, 3.1-4.4 kPa), or liver biopsy. Semaglutide is initiated at 0.25 mg once weekly and escalated every 4 weeks to a target maintenance dose of 2.4 mg. Response should be assessed with noninvasive tests after at least 18 months; a ≥30% reduction in VCTE-derived LSM suggests response. This consensus provides a structured framework for semaglutide use in MASH, integrated with management of obesity, type 2 diabetes, cardiovascular risk, and chronic kidney disease.
Institutions: Kangbuk Samsung Hospital, Sungkyunkwan University, Soonchunhyang University, Soonchunhyang University Hospital Seoul, Korea University Guro Hospital, National Evidenc- based healthcare Collaborating Agency, Yonsei University, Severance Hospital, Seoul National University, Seoul National University Bundang Hospital, Seoul National University Hospital, National Cancer Center, Seoul Metropolitan Government, SNUH SMG-SNU Boramae Medical Center, Hanyang University Seoul Hospital, Hanyang University, Inha University, Inha University Hospital, Hallym University Kangnam Sacred Heart Hospital, Asan Medical Center, University of Ulsan, Keimyung University Dongsan Hospital, Keimyung University
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $32
OpenAlex ID: W7235726613
